|
|
||||||||
Ann Thorac Surg 2005;80:896-901
© 2005 The Society of Thoracic Surgeons
a Department of Cardiac Surgery, Austin Hospital, Melbourne
b Department of Cardiology, Austin Hospital, Melbourne
c Statistical Consulting Centre, University of Melbourne, Parkville, Victoria, Australia
Accepted for publication March 23, 2005.
* Address reprint requests to Dr Buxton, Department of Cardiac Surgery, Austin Hospital, Studley Rd, Heidelberg, Victoria 3084, Australia (Email: brian.buxton{at}austin.org.au).
Presented at the Forty-first Annual Meeting of The Society of Thoracic Surgeons, Tampa, FL, Jan 2426, 2005.
| Abstract |
|---|
|
|
|---|
METHODS: Repeat angiography after primary isolated coronary artery bypass grafting was performed in 337 of 2,259 patients between July 1996 and September 2004. Patients were divided into two groups: 596 graft angiograms in 192 trial patients were compared with 389 graft angiograms in 142 nontrial patients. The mean interval from surgery was 1,306 ± 800 days versus 1,119 ± 777 days, respectively. Grafting techniques were similar in both groups except that the right internal thoracic artery was used almost exclusively as a free graft in the trial patients. Angiographic outcomes were defined as patent (stenosis <80%) or failure (stenosis
80%, occlusion, or the string sign). Comparisons of trial versus nontrial grafts were made using a generalized linear mixed model. Five-year estimates of graft patency were made using survival analyses accounting for interval censoring.
RESULTS: The odds ratio for graft failure for nontrial compared with trial patient grafts was 2.6 (95% confidence interval, 1.6 to 4.3; p < 0.001). Cumulative patency estimates for all grafts at 5 years were trial 91% versus nontrial 83%, p = 0.004. Five-year estimates for individual conduits were left internal thoracic artery, 99% versus 92%, p = 0.002; right internal thoracic artery, 86% versus 87%, p = 0.8; radial artery, 87% versus 86%, p = 0.6; and saphenous vein, 86% versus 56%, p = 0.003.
CONCLUSIONS: Graft patency rates were superior in the trial compared with nontrial patients. Symptom-directed graft failure rates were approximately double those of trial patients.
| Introduction |
|---|
|
|
|---|
Currently, there are a number of randomized trials assessing graft patencies and clinical events after coronary artery bypass graft surgery examining the differences between SV, RA, and internal thoracic artery conduits. All trials include programed angiography, which provides an opportunity to examine graft patency in asymptomatic and symptomatic patients. The Radial Artery Patency Study group has recently reported the 12-month outcome comparing 440 RA and 440 SV grafts from 561 patients [9]. The Complete Arterial Revascularization and Conventional Coronary Artery Surgery Study also reported 12-month patency of 458 grafts in 128 patients [10]. The Radial Artery Patency and Clinical Outcomes study has enrolled 612 patients in a two-tiered comparison of RA versus free right internal thoracic artery (RITA) or SV grafts during 10 years [11]. In the first year, there were 132 graft angiograms in 46 patients.
The comparison of the 1-year patency of all grafts from these protocol-directed versus symptom-directed studies [611] revealed that the patency of the internal thoracic artery, RA, and SV grafts was greater in the protocol-directed group compared with the symptom-directed groups. The differences between subsets of the RITA and SV graft patencies were significant (Fig 1).
|
| Patients and Methods |
|---|
|
|
|---|
The Radial Artery Patency and Clinical Outcomes trial compares the RA patency and clinical outcomes in two groups of patients in whom the RA (experimental) or the control graft was anastomosed to the largest nonleft anterior descending target artery. In 397 patients (<70 years) the RA was compared with the free RITA, and in 219 patients (
70 years) the RA was compared with the SV. Each patient was scheduled for one angiogram during the 10-year follow-up. Time to angiography was obtained by a second randomization to 1-, 2-, 5-, 7-, and 10-year intervals, with most repeat angiograms scheduled between 5 and 10 years [11].
The Austin Hospital database contained 1,654 patients who had a primary isolated coronary artery bypass between 1996 and 2004 and who were not included in the randomized controlled trial.
Patients
Repeat angiography was performed in 337 of 2,259 patients who underwent a primary isolated coronary artery bypass graft operation between July 1996 and September 2004. To date, 192 of the 605 (32%) patients enrolled in the randomized controlled trial received a protocol-directed angiogram. These were compared with 142 of 1,654 (8.6%) nontrial patients who had repeat angiography during the same time for symptoms of ischemia. The patient demographics are shown in Table 1.
|
80%, total occlusion, or those with a string sign.
|
| Results |
|---|
|
|
|---|
Grafts and Anastomoses
The absolute numbers of grafts and grafts per patient were greater in the trial versus nontrial patients: n = 596 (3.1 ± 0.07) versus n = 389 (2.7 ± 1.0; Tables 1 and 2). The proportion of left internal thoracic artery and RITA grafts was similar in the protocol-directed versus symptom-directed angiograms. The RITA was used almost exclusively as a free graft in the trial patients. The SV graft usage was nearly double and the RITA approximately half in the trial versus nontrial patients, which reflected the randomization process and the preference to use RAs in preference to SVs in nontrial patients (Table 2).
Generalized Linear Mixed Model
Comparison of the overall graft failure rate of nontrial versus trial patients showed an odds ratio of 2.6 (95% confidence interval, 1.6 to 4.3; p < 0.001; Table 3). These rates were adjusted for conduit, age, ventricular function, and target artery.
|
|
| Comment |
|---|
|
|
|---|
Symptom-directed angiograms are often event-driven and the data collected retrospectively. The quantification of graft disease and details of the lesions in the native coronary arteries were not recorded routinely, and these studies were not randomized. Standard statistical models assessing patency (eg, the Cox model), when used to analyze the two levels of predictive variables, patient or graft, are inappropriate. These models assume that all observations are independent, which is not so in the case of patient-related variables, which are common to all grafts in a single patient. Furthermore, the Kaplan-Meier estimates suffer from the problem that time to graft failure is unknown and are therefore invalid. Analyses of patency from such nonstandardized data are therefore not reliable.
Clinical events are likely to be related to extension of coronary artery or bypass graft disease, and therefore, clinically derived patency rates will be low. Alternatively, some asymptomatic graft failures may not be recorded, providing a relative increase, albeit small, in patency rates. The relative proportion of patients presenting with symptoms is low, and therefore most series of symptom-directed angiograms represent only a small portion of the patients who have undergone coronary artery bypass graft surgery.
The results of surgery in trial patients have been recognized as being superior to those not in the trial [14]. In trials, the surgical techniques are often standardized and the patient follow-up regimented. The trial patients in this study are reviewed at yearly intervals for assessment of symptoms and management of lipids, hypertension, and diabetes, which may have contributed to the improved outcome of coronary artery bypass grafts. In the current trial, angiography is scheduled at predetermined intervals. This trial is in progress; the mean follow-up is 4.5 years for this 10-year study, and only about one third of patients have had the protocol-directed angiogram because the number of patients scheduled for angiography was weighted to the latter years of the study when most events are expected. Complete angiographic follow-up will not be available until the study is concluded.
Selection bias of patients is likely to be a contributing factor to graft failure. The randomized controlled trial included a wide range of patients. There were exclusions of patients with left ventricular ejection fraction less than 0.30, recent myocardial infarction, body mass index greater than 35, poor lung function, and renal failure, which might bias the trial results favorably. The nontrial group had a higher proportion of women and patients with diabetes and hypertension; this could impact graft patency negatively. Although female sex, diabetes, and hypertension were significantly more likely in the symptom-directed angiography group, there were not enough graft failure end points to be able to validly control for these differences between the two groups. Although there were differences with some major patient variables, other characteristics such as left ventricular function and acuity of presentation were similar.
Longitudinal follow-up is essential. The results of the first 12 months reflect a number of factors, including surgical techniques, perioperative complications, and the properties of graft and native vessels, as well as patient variables [111]. The mean follow-up of the current trial and nontrial patients, who had repeat angiograms, is approximately 3 years, which is a short duration relative to the expected long-term patency, especially of arterial conduits. Further follow-up will be needed to determine the true biologic differences among the conduits [15].
Limitations
A single angiogram provides restricted information about graft patency. Selective angiography is invasive, and computed tomographic angiography requires exposure to similar doses of radiation; therefore, neither of these studies lends itself to repeated observations in the same patient. Although repeated observations may be useful in obtaining a more complete picture of graft function, it is difficult to justify the increased risk to an asymptomatic patient in a clinical trial. For these reasons, trial patients were scheduled for only one postoperative angiogram.
The precise relationship of trial data to the broader population of patients having coronary artery bypass grafting is unknown. The patency results of programed angiography demonstrate what can be obtained in a population defined by the trial entry criteria [11].
Conclusions
Coronary artery bypass graft failure rate in patients with ischemia was about double that of patients in the clinical trial. Angiography, after evidence of ischemia, underestimates graft patency.
Implication
Angiogram results from trials, compared with symptomatic patients, is more representative of those from the overall coronary artery surgical population; the trial results are more relevant and should be considered as the standard by which grafts are compared in the future.
| Notice From the American Board of Thoracic Surgery Regarding Trainees and Candidates for Certification Who Are Called to Military Service Related to the War on Terrorism |
|---|
|
|
|---|
Timothy J. Gardner, MD Chairman
The American Board of Thoracic Surgery
| Discussion |
|---|
|
|
|---|
By definition, patients in the symptomatic group represented a very huge subset with a specific condition of ischemia. None of the asymptomatic patients in the rest of cohort was represented. Similarly, the RAPCO trial group consisted of very specific patients based on rather strict inclusion/exclusion criteria such as ejection fraction greater than 35%, a minimal target vessel diameter greater than 1.5 mm, or expected survival greater than 10 years. Thus, the patients in RAPCO trial were very different, yet equally skewed, and they were far from being the representative sample of the entire cohort.
The sampling criteria were very different between the two groups. As expected, fundamental differences were present that could have accounted for different incidences of ischemic symptoms and graft patency. For example, the symptomatic group had a significantly higher incidence of female gender, 30% versus 11%, diabetes, 37% versus 14%, and hypertension, 65% versus 48%. Also, the number of bypass grafts was lower, 2.7 versus 3.1.
A substantial portion of symptomatic patients was likely to have had small target coronary vessels given the higher incidence of female gender and diabetes. Patients with target vessel diameter less than 1.5 mm were included in the symptomatic group unlike RAPCO trial group. Therefore, the observed difference in graft patency may have been a mere reflection of two very different sampling processes. Since the samples were not equivalent, any type of statistical comparison was invalid. Furthermore, one may not draw any conclusion about the overall cohort based on these nonrepresentative samples.
Ischemic symptoms may be a poor surrogate marker of graft patency. "Graft failure, which may be silent... and rates of failure will therefore be underestimated" wrote Dr. Buxton in his previous publication.
It is very tempting to expand our knowledge base by inferring and generalizing from a smaller observation. Of course, we are all eager to know the true patency rates of coronary bypass grafts. Unfortunately, we cannot draw such a conclusion from this study. I would like to thank the chairman and the Society for the opportunity to discuss and share my thoughts on this paper.
DR BUXTON: I would like to thank Dr. Park for his criticisms and comments. The prime criticism is that we really dont have the results from the wider population of patients having coronary artery bypass grafts. All we can do is gradually get closer. We believe that perhaps the trial patients with all the exclusionsand there are not that manybetter represent the overall population. However, I accept that criticism.
Secondly, there is no apology for the differences between the patient groups, that is the way it is. It is not surprising that there are more adverse risk factors in the symptomatic group of patients than in the trial patients. The number of vessels in each study was slightly skewed because the trial did not include patients with any single vessel grafts.
I do agree with the fundamental thrust of Dr. Parks comments, that it really is very difficult to obtain the truth, unless we have an angiogram every day or every month in the whole population, it is not possible to obtain true graft patencies. The trial patients do represent another cohort of patients which perhaps gives us wider representation and provide graft patencies which are closer to the truth.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. Tatoulis, B. F. Buxton, J. A. Fuller, M. Meswani, S. Theodore, N. Powar, and R. Wynne Long-term patency of 1108 radial arterial-coronary angiograms over 10 years. Ann. Thorac. Surg., July 1, 2009; 88(1): 23 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. F. Buxton, P. A.R. Hayward, A. E. Newcomb, S. Moten, S. Seevanayagam, and I. Gordon Choice of conduits for coronary artery bypass grafting: craft or science? Eur. J. Cardiothorac. Surg., April 1, 2009; 35(4): 658 - 670. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Brown, H. V. Schaff, and T. M. Sundt Conduit choice for coronary artery bypass grafting after mediastinal radiation. J. Thorac. Cardiovasc. Surg., November 1, 2008; 136(5): 1167 - 1171. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Glineur, C. Hanet, A. Poncelet, W. D'hoore, J.-C. Funken, J. Rubay, P. Astarci, V. Lacroix, R. Verhelst, P. Y. Etienne, et al. Comparison of saphenous vein graft versus right gastroepiploic artery to revascularize the right coronary artery: a prospective randomized clinical, functional, and angiographic midterm evaluation. J. Thorac. Cardiovasc. Surg., August 1, 2008; 136(2): 482 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A.R. Hayward and B. F. Buxton Contemporary Coronary Graft Patency: 5-Year Observational Data From a Randomized Trial of Conduits Ann. Thorac. Surg., September 1, 2007; 84(3): 795 - 799. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Nezic, A. M. Knezevic, P. S. Milojevic, B. P. Dukanovic, M. D. Jovic, M. D. Borzanovic, and A. N. Neskovic The fate of the radial artery conduit in coronary artery bypass grafting surgery. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 341 - 346. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |